Progress in Study on the Clinical Application of Dexmedetomidine

万晓波,彭树飞,闫向勇,周立业,邹玉梅
DOI: https://doi.org/10.13241/j.cnki.pmb.2013.07.032
2013-01-01
Abstract:Dexmedetomidine is a potent and highly selective a2-adrenoceptor agonist.It has the ratio of a2/a1 is 1620:1.Its half-life of distribution is about 6 minutes and the elimination half-life is about 2 hours.Dexmedetomidine is mainly dissolved by the liver.A large number of laboratory and animal studies have been performed,as have clinical trials enrolling healthy volunteers or patients with the aim of shedding shed light on the main pharmacological features of dexmedetomidine.It provides dose-dependent sedation,analgesia,anxiolysis and sympatholysis with less and light side-effects.The hypnotic and supraspinal analgesic effects of dexmedetomidine are mediated by the hyperpolarization of noradrenelgic neurons,which suppresses neuronal firing in the locus ceruleus along with inhibition of norepinephrine release and activity in the descending medullospinal noradrenergic pathway,secondary to activation of central a2-ARs.It was proved for adult sedation and analgesia use in the intensive care unit(ICU)in the USA in l999.As a result of these properties,it has been successfully used in the Premedication,intrathecal anesthesia,postoperative analgesia and as an adjunct to general anesthesia.This review focuses on the advances of its clinical use.
What problem does this paper attempt to address?